To estimate by how much, and how quickly, a given reduction in serum cholesterol concentration will reduce the risk of ischaemic heart disease (IHD).
1. Cohort studies were combined using a log linear model to investigate the relationship between risk of IHD and serum cholesterol concentration. Age-adjusted rate of IHD was weighted by the number of events 2. International studies: for each study, incidence of mortality from IHD (in logarithms) was regressed in the constituent communities on the cholesterol concentration associated with the mean risk in each community. The analysis weighted the age-adjusted rate of IHD by the number of events. Smoking, blood-pressure and cholesterol were included as independent variables.
3. RCTs were divided into 3 time periods: less than 2, 2.1 to 5 and 5.1 to 12 years after entry. Unpublished data on mortality were supplied by authors of 8 RCTs, and numbers of events were estimated from survival curves for 2 trials. The average reduction in IHD over each time period was estimated by logistic regression that combined the odds ratios from each trial to obtain a summary relative odds estimate. Each trial was weighted by the mean difference in thetotal cholesterol concentration between treatment and control groups.
Results were expressed as the decrease in the risk of IHD associated with a decrease in serum cholesterol concentration of 0.6 mmol/l.
How were differences between studies investigated?
Differences in RCTs were investigated for those trials indicating similar diagnostic criteria for death from IHD and nonfatal myocardial infarction. There was no significant heterogeneity between estimates relating to trial duration.
Results of the review
Ten cohort studies, each recording more than 350 IHD events (deaths and, in 3 studies, nonfatal infarcts): 494,804 men and 18,811 events recorded; 54,832 women and 4,097 events recorded.
Three international studies: number of participants not given.
Twenty-eight published RCTs that recruited 46,254 men and recorded 4,241 events.
1. For cohort studies, a decrease in cholesterol concentration of 0.6 mmol/l was associated with a decrease in the risk of IHD by 54% at age 40, 39% at age 50, 27% at age 60, 20% at age 70 and 19% at age 80.
2. With international studies, a difference in cholesterol concentration of 0.6 mmol/l was associated with a difference in mortality from IHD of, on average, 38% (95% confidence interval, CI: 33, 42) in men. The mean age at death ranged from 55 to 64 years in all studies. Differences in serum cholesterol concentration explained over 80% of the international variation in mortality from IHD.
3. RCTs involving men demonstrated a dose-response association, i.e. trials achieving a greater reduction in serum cholesterol concentration generally showed a greater reduction in IHD (P<0.001).
The reductions in IHD increased with increasing duration of reduced cholesterol levels, and were 7% (95% CI: 0.0, 14, P=0.06) in the first 2 years, 22% (95% CI: 15, 28, P<0.001) from 2.1 to 5 years, and 25% (95% CI: 15, 35, P<0.001) from 5.1 to 12 years; all per 0.6 mmol/l reduction in cholesterol concentration.
The international estimates for women were similar to those for men. Three RCTs with separate data for women showed a significant reduction in IHD, similar in size to that observed in men in the same trials, whereas a fourth trial suggested no effects in women. Different patterns of serum cholesterol concentration in women make it difficult to draw firm conclusions from the studies.
